Updated:
Purple Biotech Ltd.
Purple Biotech Ltd. is an oncology-focused biotech firm with platforms for immunotherapy and solid tumor treatments.
Purple Biotech Ltd.
Purple Biotech Ltd. was originally incorporated as a biotechnology research company and has since pivoted toward clinical-stage oncology. The firm's wealth is derived from public equity markets and strategic investors, not a single family fortune. It trades on the Tel Aviv Stock Exchange under the ticker PPBT, reflecting its status as a publicly held entity. Strategy centers on two proprietary platforms: the CM24 immunotherapy targeting CEACAM1, and a tri-specific antibody platform for solid tumors. The firm deploys capital across preclinical and Phase 1/2 clinical trials, with a geographic presence in Israel and the United States. Pipeline candidates include NT219 for pancreatic cancer and TTAC-0001 for glioblastoma, as disclosed in regulatory filings. It relies on licensing and local partnerships for drug development. The firm reports 2025 equity capital and investments, though exact AUM is not public. It employs around 30 professionals based on public filings. No known adjacent charitable vehicles or club memberships are publicly associated. A 2024 corporate update highlighted the firm's cash position and development timeline. A key structural differentiator is its publicly traded status, which subjects it to regulatory scrutiny and quarterly reporting. This governance model is distinct from private biotech firms, as capital is raised through stock offerings rather than private fundraises.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Who runs investment decisions at Purple Biotech Ltd.?
Investment decisions are made by the board of directors and executive management, including the CEO and Chief Financial Officer. The firm's public status means major capital allocations are subject to board approval and shareholder oversight, per regulatory filings.
Is Purple Biotech structured as a family office or a public biotech firm?
Purple Biotech is a publicly traded biotech company, not a family office. It raises capital through public offerings and institutional investments, and its governance follows standard corporate structure with a board and executive team.
What investment stages does Purple Biotech typically target?
The firm invests in preclinical and clinical-stage oncology drug development, with a focus on Phase 1 and Phase 2 trials. It does not typically invest in later-stage or commercial assets, instead advancing its own pipeline through development.
Which sectors does Purple Biotech explicitly focus on?
Purple Biotech concentrates on oncology and the development of immunotherapies for solid tumors. It does not explicitly avoid other sectors, but its publicly stated pipeline is entirely in cancer treatment.
Does Purple Biotech maintain philanthropic structures?
There is no publicly disclosed philanthropic arm. As a publicly traded firm, any charitable activities would be reported in corporate filings, but none are evident in available records.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: